94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Francesca Palermo1,2†
Nicola Pieroni1,3†
Laura Maugeri1
Ginevra Begani Provinciali1
Alessia Sanna1
Inna Bukreeva1
Lorenzo Massimi1‡
Maura Catalano1
Margie P. Olbinado4Michela Fratini1
Antonio Uccelli5,6Giuseppe Gigli7
Nicole Kerlero de Rosbo5§
Claudia Balducci8§
Alessia Cedola1*§- 1TomaLab, Institute of Nanotechnology, CNR, Rome, Italy
- 2Dipartimento di Fisica, Università della Calabria, Rende, Italy
- 3Dipartimento di Morfogenesi e Ingegneria Tissutale, Sapienza Università di Roma, Rome, Italy
- 4Swiss Light Source, Paul Scherrer Institut X-ray Tomography Group, Villigen, Switzerland
- 5Department of Neurosciences, Rehabilitation, Ophthalmology and Maternal-Fetal Medicine (DINOGMI), University of Genoa, Genoa, Italy
- 6Ospedale Policlinico San Martino IRCCS, Genoa, Italy
- 7Institute of Nanotechnology, CNR, Università del Salento, Lecce, Italy
- 8Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
A Corrigendum on
X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases
by Palermo, F., Pieroni, N., Maugeri, L., Provinciali, G. B., Sanna, A., Bukreeva, I., et al. (2020). Front. Neurosci. 14:584161. doi: 10.3389/fnins.2020.584161
In the original article, there were several errors, as detailed below.
Author List, Affiliations, and Author Contributions
Giuseppe Gigli was not included as an author in the published article. The corrected Author Contributions Statement appears below.
Author Contributions
AC, CB, and NKdeR conceived and designed the experiments and participated to the discussion of the results and wrote the manuscript. MF, FP, NP, LM, GP, AS, and AC performed the experiments and contributed to the data analysis. IB, AC, MF, FP, NP, LM, GP, AS, IB, and GG have contributed to the discussion of the results and to the final revision of the manuscript. MC performed the data analysis. All the authors contributed to the final writing of the manuscript.
In the original article, the affiliation for author Giuseppe Gigli was also not included. We have added the affiliation for Giuseppe Gigli as 7 - Institute of Nanotechnology, CNR, Università del Salento, Lecce, Italy.
Additionally, there was an error in the order of the authors in the author list of the original article. Inna Bukreeva should be the sixth author in the list. The original article has now been updated.
Text Corrections
In the original article, there was a mistake in the caption for Figure 1 as published. Figure 1A was adapted from Figure 3F of T. Zikmund et al 2018 JINST 13 C02039, but the reference to the paper was erroneously omitted. The corrected caption appears below.
Figure 1. XPCT is a powerful technique that provides high-contrast resolution without requirement for a contrast agent. The image shown puts together parts of naïve mouse brain with the left side assessed by standard X-ray micro-tomography with a mixture of 1% iodine and 90% methanol as contrast agent (A) as reported in Zikmund et al. (2018) JINST 13 C02039, while the right side was generated by XPCT (B). Small variations in density appear much more evident in XPCT imaging. Both images were obtained as z-projection of maximum intensity over 300 μm.
In addition, the full citation for Zikmund et al. (2018) JINST 13 C02039 will be added to the reference list of the original article.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
References
Keywords: X-ray phase contrast tomography, preclinical disease models, Alzheimer's disease, multiple sclerosis, 3D imaging
Citation: Palermo F, Pieroni N, Maugeri L, Provinciali GB, Sanna A, Bukreeva I, Massimi L, Catalano M, Olbinado MP, Fratini M, Uccelli A, Gigli G, Kerlero de Rosbo N, Balducci C and Cedola A (2021) Corrigendum: X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases. Front. Neurosci. 15:657368. doi: 10.3389/fnins.2021.657368
Received: 22 January 2021; Accepted: 27 January 2021;
Published: 17 February 2021.
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2021 Palermo, Pieroni, Maugeri, Provinciali, Sanna, Bukreeva, Massimi, Catalano, Olbinado, Fratini, Uccelli, Gigli, Kerlero de Rosbo, Balducci and Cedola. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alessia Cedola, YWxlc3NpYS5jZWRvbGFAY25yLml0
†These authors have contributed equally to this work and share first authorship
‡Present address: Lorenzo Massimi, Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom
§These authors have contributed equally to this work and share last authorship